Open reading frame

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

Retrieved on: 
Tuesday, May 30, 2023

BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.

Key Points: 
  • BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
  • The ultimate goal is to develop phage-based immunotherapeutics capable of treating a range of immune disorders including cancer.
  • The primary focus of the company lies in Colorectal cancer and Pancreatic cancer.
  • Alkalihalobacillus clausii has been identified as a representative microbiome, and iNtRON has obtained the strain and confirmed the presence of Prophage and Jamphage through the genomic analysis.

Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing

Retrieved on: 
Thursday, December 15, 2022

Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing tools, today announced the publication of data in Nature Communications describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor to date.

Key Points: 
  • Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing tools, today announced the publication of data in Nature Communications describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor to date.
  • These nucleases are highly active and have broad targeting potential to enable a variety of genome editing and therapeutic applications.
  • The nucleases were uncovered and characterized by Metagenomi researchers, who mined the companys extensive, proprietary genome-resolved metagenomics database and rapidly developed them into gene editing systems.
  • Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot.

GenScript Launches Expedited mRNA Service for Research and Pre-Clinical Applications

Retrieved on: 
Wednesday, August 17, 2022

PISCATAWAY, N.J., Aug. 17, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only (RUO) and pre-clinical messenger RNA (mRNA) synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks.

Key Points: 
  • By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks.
  • mRNA provides new therapeutic opportunities for a range of diseases, and scientists need expedited, access to robust, custom mRNA to synthesize the proteins used to engineer personalized medicines.
  • In contrast, GenScript's IVT mRNA service spans the entire workflow, from gene synthesis to mRNA production.
  • "The new IVT mRNA production service solves mRNA researchers' challenges of sourcing and communicating among multiple vendors and de-risks the synthesis of highly optimized mRNA designs."